Literature DB >> 28091345

Propofol as a Risk Factor for ICU-Acquired Weakness in Septic Patients with Acute Respiratory Failure.

Peter A Abdelmalik1, Goran Rakocevic2.   

Abstract

BACKGROUND: Critical illness polyneuropathy (CIN) and critical illness myopathy (CIM), together "ICU-Acquired weakness (ICUAW)," occur frequently in septic patients. One of the proposed mechanisms for ICUAW includes prolonged inactivation of sodium channels. Propofol, used commonly in patients with acute respiratory failure (ARF), primarily acts via enhancement of GABAergic transmission but may also increase sodium channel inactivation, suggesting a potential interaction.
METHODS: Electronic medical records and EMG reports of patients with ICUAW and a diagnosis of either sepsis, septicaemia, severe sepsis, or septic shock, concurrent with a diagnosis of acute respiratory failure (ARF), were retrospectively analyzed in a single center university hospital.
RESULTS: 74 cases were identified (50.0% men, age 58±14 years), and compared to age- and sex-matched controls. Of these, 51 (69%) had CIN, 19 (26%) had CIM, and 4 (5%) had both. Propofol exposure was significantly higher in patients with ICUAW compared to controls (63.5% vs. 33.8%, p<0.001). The odds ratio of developing ICUAW with propofol exposure was 3.4 (95% CI:1.7-6.7, p<0.001). Patients with ICUAW had significantly more days in hospital (59±44 vs. 30±23) and ICU (38±26 vs. 17±13), days dependent on mechanical ventilation (27±21 vs. 13±16), and rates of tracheostomy (79.7% vs. 36.5%) and gastrostomy (75.7% vs. 25.7%) (all p<0.001). They also received a significantly higher number of distinct intravenous antibiotics, cumulative days of antibiotic therapy, and exposure to vasopressors and paralytics.
CONCLUSIONS: Propofol exposure may increase the risk of ICUAW in septic patients. An interaction through sodium channel inactivation is hypothesized.

Entities:  

Keywords:  Critical care; Intensive care; Paralysis; Paresis

Mesh:

Substances:

Year:  2017        PMID: 28091345     DOI: 10.1017/cjn.2016.424

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

1.  Effect of propofol, midazolam and dexmedetomidine on ICU patients with sepsis and on arterial blood gas.

Authors:  Jia Ding; Yuwen Chen; Yuan Gao
Journal:  Exp Ther Med       Date:  2019-10-09       Impact factor: 2.447

Review 2.  Use of dexmedetomidine in patients with sepsis: a systematic review and meta-analysis of randomized-controlled trials.

Authors:  Ting Zhang; Qimin Mei; Shabai Dai; Yecheng Liu; Huadong Zhu
Journal:  Ann Intensive Care       Date:  2022-08-27       Impact factor: 10.318

3.  Effects of propofol on intracranial pressure and prognosis in patients with severe brain diseases undergoing endotracheal suctioning.

Authors:  Menghang Wu; Xiaorong Yin; Maojun Chen; Yan Liu; Xia Zhang; Tingting Li; Yujuan Long; Xiaomei Wu; Lihui Pu; Maojie Zhang; Zhi Hu; Ling Ye
Journal:  BMC Neurol       Date:  2020-10-29       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.